Tidy up your labs, biotech. Pfizer is coming with 'significant firepower' and cash to burn

The world’s biotechs would be wise to polish up their shop windows, tidy up their benches and straighten up their lab coats: Pfizer is coming.

Inquiring minds have wanted to know: What does Pfizer, loaded up with buckets of cash from the successful COVID-19 vaccine Comirnaty, want to buy? Well, the New York Big Pharma doled out a bit of that bounty today with its $6.7 billion Arena Pharmaceuticals buyout.

And in talking about how that biotech will fit into Pfizer’s portfolio, executives gave a preview of what else they want.